A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This study is to determine the Maximal Tolerated Dose (MTD), the Dose Limitant Toxicities
(DLTs) and the safety profile of S-1 combined with fixed doses of Irinotecan (SIRI schedule)
and fixed doses of Irinotecan and Oxaliplatin (SIRINOX schedule).